In type 1 diabetes, a renewable source of human pancreatic b cells, in particular from human induced pluripotent stem cell (hiPSC) origin, would greatly benefit cell therapy. Earlier work showed that pancreatic progenitors differentiated from human embryonic stem cells in vitro can further mature to become glucose responsive following macroencapsulation and transplantation in mice. Here we took a similar approach optimizing the generation of pancreatic progenitors from hiPSCs. This work demonstrates that hiPSCs differentiated to pancreatic endoderm in vitro can be efficiently and robustly generated under large-scale conditions. The hiPSC-derived pancreatic endoderm cells (HiPECs) can further differentiate into glucose-responsive islet-like cells following macroencapsulation and in vivo implantation. The HiPECs can protect mice from streptozotocin-induced hyperglycemia and maintain normal glucose homeostasis and equilibrated plasma glucose concentrations at levels similar to the human set point. These results further validate the potential use of hiPSC-derived islet cells for application in clinical settings.
INTRODUCTION
Diabetes currently affects about 400 million people worldwide, of which type 1 diabetes (T1D) accounts for up to 5%-10%. Indeed, T1D was recognized early in the era of regenerative medicine research as an indication for a stem cell-based therapy as it results from the lack of insulin due the loss of pancreatic b cells. In these patients blood glucose homeostasis must be controlled through the injection of insulin. An alternative approach is the transplantation of islets or b cell preparations obtained post-mortem from organ donors. Although success rates have increased, the duration of insulin independence following transplantation is usually restricted to a few years (Shapiro et al., 2000) . The rate-limiting step for the widespread use of islet cell transplantation is a reproducible unlimited supply of functional beta/islet cells. Regenerative medicine approaches therefore represent an important possibility for achieving this breakthrough. Over the last decade, significant advancements have been made to develop alternative b cell replacement therapies using a renewable source of differentiating cells such as human pluripotent stem cells. Endoderm patterning principles have been mimicked in vitro to differentiate human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) into pancreatic endoderm cells (PECs) that express the transcription factors NKX6-1 and PDX1 (D'Amour et al., 2006; Nostro et al., 2011; Nostro et al., 2015) . In vivo implantation of such ESC-derived PECs led to further differentiation and maturation into insulin-producing cells, culminating in the first clinical trial using stem cell therapy for T1D (ViaCyte, Inc., clinical trials identifier: NCT02239354) (D'Amour et al., 2006; Jiang et al., 2007; Kroon et al., 2008; Zhang et al., 2009; Kelly et al., 2011; Rezania et al., 2012) . The recent discovery that it is possible to derive hiPSCs from somatic cells has raised the possibility that b cells can be derived from patients themselves through cell reprogramming and differentiation. While the use of pluripotent stem cells is the most promising strategy for cell replacement therapy, it may not prevent the need for immunosuppressant drugs in the context of T1D with islet-specific autoantibodies. Although improvements of immunosuppression protocols have been made, they are still associated with impaired b cell regeneration and function (Dominguez-Bendala et al., 2016; Shapiro, 2011) . Recently, a macroencapsulation device has been put forward as a means to protect b cells from host immunoreactivity (Kumagai-Braesch et al., 2013) . Macroencapsulation devices are cell-impermeable porous membrane cassettes employed to encase and immunoprotect the engrafted cells. It has been shown that macroencapsulation and more recently microencapsulation of hESC-derived pancreatic progenitors differentiated into b cells could partially rescue streptozotocin (STZ)-induced hyperglycemia without triggering an immune response (Kroon et al., 2008; Lee et al., 2009; Robert et al., 2018; Vegas et al., 2016) . In the present study we assessed the potential of hiPSCs to efficiently differentiate into pancreatic progenitors in a scalable and reproducible process. Further, we investigated the capacity of the hiPSC-derived pancreatic progenitor cells to survive and mature within planar macroencapsulation devices in vivo to levels allowing prevention of hyperglycemia in animals after ablation of mouse b cells using STZ.
RESULTS
In Vitro Characterization of hiPSC Differentiation into Pancreatic Endoderm Cells hiPSCs were differentiated into PECs using an optimized version of a four-stage protocol published previously (D'Amour et al., 2005; D'Amour et al., 2006; Kroon et al., 2008) . Two hiPSC lines derived from different donors were initially cultured as monolayers and controlled for pluripotency by flow cytometry (data not shown) before initiating 12 days of differentiation under threedimensional culture conditions. Quantitative gene expression analysis revealed specific patterns recapitulating the different stages of differentiation in normal endocrine development and showed consistency between the two hiPSC lines (Figures 1A-1I ). During the first 2 days of differentiation, induction of endoderm fate occurs. hiPSCs lose the expression of pluripotency markers (NANOG, POU5F1, and SOX2) and start expressing the mesoendodermal stage-specific marker T-box transcription factor T (TBXT) and then the definitive endoderm-specific markers SOX17 and CXCR4 ( Figures 1A-1F ). This stage is followed by specification of primitive gut tube together with upregulation of HNF1B and HNF4A (data not shown) at day 5 before expressing markers of posterior foregut as indicated by increased expression of SOX9 and PDX1 at day 8 of differentiation (Figures 1G and 1H) . By day 12, NKX6-1 gene expression levels are dramatically increased ( Figure 1I ), indicating the beginning of pancreatic endocrine specification. At this time point, a large proportion of endodermal chromogranin A-negative/PDX1-positive cells also express NKX6-1 (49.03% ± 6.1%) as shown by immunofluorescence and flow cytometry analyses (Figures 1J, 2A, 2B, and 2D) . These cells are considered pancreatic endocrine progenitors and will be referred to as PECs throughout, while the aggregates will be named hiPSC-derived PECs (HiPECs). A small proportion of cells express CDX2 and/or AFP (14.06% ± 1.8%) and likely represent off-target gut endoderm cells (Figures 2C and 2D) . Moreover, a small percentage of differentiating chromogranin A-positive cells (total endocrine, Figures 2A and 2D, 19 .77% ± 4.7%) is detected, which mainly represents cells co-expressing insulin and glucagon ( Figure 1K ) or insulin and somatostatin (not shown). Similar cell populations have been identified in PECs derived from hESCs (Robert et al., 2018) . The four-stage differentiation protocol of hiPSCs into pancreatic endocrine progenitors described here was further adapted to large-scale culture conditions following a previously published protocol using hESCs (Schulz, 2015; Schulz et al., 2012) . Typically, large-scale production was initiated from 3-7 * 10 9 hiPSCs in 30,000-40,000 cm 2 . The timing of gene expression of small-versus large-scale culture similarly recapitulated the four-stage differentiation process (data not shown).
In large-scale aggregates (herein named LHiPECs), the percentage of PECs was comparable at day 12 to small-scale generated HiPECs (HiPECs, 49.03% ± 6.1%; LHiPECs, 46.22% ± 3.04%) ( Figures 2D-2F ). Moreover, LHiPECs could be frozen and stored without losing their differentiation status as shown by flow cytometry analyses of LHiPECs after cryopreservation and thawing (Figures 2G and 2H) . Taken together, these results show that the four-stage differentiation protocol allows the differentiation of hiPSCs into pancreatic endoderm expressing the appropriate sets of genes and proteins consistent with this stage of differentiation. Moreover, these data demonstrate that the method is reproducible, robust, and scalable for production of large batches of PECs of high quality that can be cryopreserved prior to further use.
Macroencapsulated hiPSC-Derived Pancreatic Endoderm Generates Functional Endocrine Cells
In Vivo To investigate whether in vitro-produced HiPECs have the potential to generate functional endocrine cells in vivo, we used a flat-sheet macroencapsulation device to graft the HiPECs under the skin (neck) of immune-compromised mice (Lathuiliere et al., 2014) . We initially determined and set the optimal volume of cells to engraft at 45 mL (4-5 * 10 6 cells) of aggregates ( Figure S1 ). Starting at 8 weeks post-implantation, we investigated the efficiency of b cell differentiation in vivo by analyzing changes in serum human c-peptide release during glucose challenges (Figures 3A and 3A 0 ). At 8 weeks post-implantation, very low levels of human c-peptide (<100 pM at 60 min) were detected in response to glucose administration ( Figure 3A ). Four weeks later, an increase in c-peptide levels was observed (315.1 ± 19.92 pM) 60 min after glucose administration. With increasing number of weeks in vivo, both fasting and glucose-stimulated human c-peptide levels continued to rise to reach a maximum of 292 ± 34.63 pM at fasting and 1,203 ± 178 pM at 60 min peak levels in response to glucose after 18 weeks post-implantation ( Figure 3A ). These results were consistent with encapsulated cells derived from different parental hiPSC lines ( Figure 3C ). Moreover, similar results were observed in mice implanted with LHiPECs ( Figure 3A To further characterize the role of HiPEC-derived endocrine cells in the regulation of glucose metabolism in vivo, we compared the serum levels of human c-peptide and glucose clearance over time. In this analysis both mouse islet b cells and implanted human b cells contributed to lower blood glucose levels during the tolerance test. As human insulin secretion measured by c-peptide analysis increased with time following implantation, this may exaggerate the corrective action of insulin on glucose homeostasis. Indeed, after 20 to 22 weeks of implantation of either HiPECs or LHiPECs, glucose clearance was significantly accelerated compared with animals carrying the macroencapsulated cells for only 8 weeks ( Figures 3B and 3B 0 ). Enhanced correction of glucose excursions occurred over the same time frame as graft-derived human c-peptide increased (Figures 3A , 3B, 3A 0 , and 3B 0 ). In parallel, fasting blood glucose levels decreased (from 99.06 ± 3.2 mg/dL at 8-9 weeks post-implantation to 87.67 ± 4.3 mg/dL at 20 weeks) ( Figure 3B ). Similar changes in fasting blood glucose levels were observed in animals implanted with LHiPECs ( Figure 3B 0 ). Altogether these data strongly suggest that insulin release from implanted hiPSC-derived PECs is under glucose control and significantly contributes to glucose homeostasis in the host. Ex Vivo Characterization of HiPEC-Derived GlucoseResponsive Insulin-Producing Cells To characterize the cellular content of the devices, we performed immunohistochemical analyses of explanted grafts 32 weeks post-implantation. The H&E staining of sectioned devices revealed the homogeneous formation and distribution of a three-dimensional, organized tissue derived from HiPECs, while conjunctive tissue (c) as well as vessels (dotted lines) was detected on the outer surface of the device but not in direct contact with cells present inside ( Figure S2 ). We clearly identified epithelial endocrine tissue (straight lines), as well as ductal structures (d) surrounded by connective tissue (*) ( Figure S2 ). Also, insulin staining revealed a high proportion of cells expressing insulin in islet-like structures and a wide distribution of insulin-positive cells throughout the device (Figures 4A and S2) . Subsequent immunofluorescence labeling for endocrine hormones, i.e., insulin, glucagon, somatostatin, and ghrelin, showed that typical grafts contained multiple cell clusters individually expressing each hormone in a heterogeneous cellular architecture reminiscent of either fetal or more mature pancreatic islets ( Figures 4B-4D) . A small proportion of glucagon cells also expressed c-peptide, representing rare polyhormonal cells present in the explants ( Figure 4C ). Apart from the endocrine population, we also observed ductal ( Figures S2, S3A , and S3B) and mesenchymal cells ( Figure S3C ), which express CK19 and vimentin, respectively. However, we did not detect positive cells for CDX2, albumin, and amylase (data not shown). This is in agreement with the absence of exocrine, intestinal, and hepatic transcripts in explanted grafts ( Figures  S3D and S3F) . Moreover, we did not detect remaining pluripotent cells or teratoma formation in the explants ( Figure S3G and data not shown). Accordingly, in a recent longitudinal proteomic profiling study (Haller et al., 2018) of PEC differentiation in vivo, we could not detect any protein corresponding to those off-target tissues after 16 weeks of implantation.
HiPEC-derived tissue contained more than 50% endocrine cells, with 23.79% ± 3.19% c-peptide positive, 5.88% ± 0.73% glucagon positive, 7.15% ± 1.11% somatostatin positive, 2.79% ± 0.54% pancreatic polypeptide positive, and 11.00% ± 1.32% expressing ghrelin ( Figure 4E ). Similar to the proportion of c-peptide-positive cells, 24.86% ± 3.28% of total cells expressed insulin, which suggests that more than 95% of insulin cells also express c-peptide (Figures 4E and 5A and data not shown). Gene expression analysis of the grafts confirmed the presence of insulin, glucagon, somatostatin, and ghrelin as well as MAFA and NKX6.1 transcripts ( Figures 4F, 5B , S4, S5A, and S5B). Indeed, MAFA and NKX6.1 are two important transcription factors involved in the function and the maintenance of the glucose-responsive phenotype of mature b cells (Matsuoka et al., 2004; Zhang et al., 2005) . Compared with human islets obtained from adult post-mortem donors, insulin and somatostatin expression was lower in the grafts ( Figure 4F ). This can be explained by the dilution of the endocrine population in the explant grafts compared with control human islet preparations. However, glucagon and ghrelin were expressed at slightly higher levels than those measured in human islets, which could suggest a bias in the differentiation potential or the prevalence of a progenitor state. We could quantify similar percentages of cells positive for insulin (24.86% ± 3.28%; n = 6), NKX6-1 (21.52% ± 2.31%), and MAFA (22.02% ± 2.86%) ( Figure 5A ). Co-localization analysis also showed that the majority of the insulin-positive cells were positive for NKX6-1 and/or MAFA ( Figure 5C ). These different hormones and transcription factors are hallmarks of fully differentiated pancreatic endocrine cells and emphasize the fact that a reasonable fraction of HiPEC-derived endocrine cells have reached a mature phenotype. 
Macroencapsulated HiPEC-Derived Endocrine Cells Protect Mice against STZ-Induced Hyperglycemia
The ultimate test to validate the functionality of HiPECderived endocrine cells is to assess their ability to regulate blood glucose levels independent of the endogenous mouse pancreatic b cells. We showed earlier that macroencapsulated HiPEC-derived b cells improved glucose clearance after glucose challenge over time. To further investigate the ability of grafted cells to tightly regulate glucose levels, engrafted mice were treated with the b cell toxin STZ. To exert its toxic function, STZ enters b cells through the glucose transporter SLC2A2 (GLUT2). Human b cells express relatively low levels of SLC2A2 and are therefore protected from STZ cytotoxicity at doses that eliminate mouse b cells (Yang and Wright, 2002) . As expected, animals with levels of circulating human c-peptide below 100 pM (animals A1 and A2) became hyperglycemic after STZ treatment, showing the efficiency of the murine b cell depletion ( Figures 7A and 7C ). In contrast, animals with circulating human c-peptide levels over 500 pM maintained normoglycemia ( Figures 7A-7C) . Indeed, murine c-peptide levels induced by a glucose challenge in mice are normally around 500-600 pM at peak, which suggests that this level of human c-peptide is adequate to improve glucose control. Also, when comparing the profiles of human c-peptide secretion after glucose injection before and after STZ treatment, we observed that the engrafted cells maintained their function at maximal values, with the highest peak of secretion after 30 min ( Figure 3A ). This observation was independent of the cell source used for the implantation (HiPEC versus LHiPEC). Interestingly, glucose clearance efficiency was significantly improved in animals after STZ treatment compared . Average values exclude animals A1, A2, and A3 that lost glucose control due to the absence of human c-peptide secretion. At day 74 post-STZ (10 weeks), mice were explanted and blood glucose levels were monitored post-explantation. (C 0 ) Independent and (D 0 ) average values of non-fasting blood glucose levels measured before and for 68 days after STZ treatment (STZ at 25 weeks post-engraftment time) in 9 animals implanted with LHiPECs. At day 67 post-STZ (9 weeks), mice were explanted and blood glucose levels were measured post-explantation. Error bars represent SEM.
with the same animals before STZ treatment. Indeed, blood sugar rise after glucose challenge was significantly lower and returned to baseline more rapidly ( Figures 3B, 3B 0 , and 7B). These results suggest that engrafted cells further mature with time and/or when full contribution is needed. As demonstrated, basal blood glucose levels of animals post-STZ remained tightly controlled for several weeks after treatment ( Figures 7C and 7D) . The control of glycemia in animals implanted with LHiPECs was more unstable following STZ and we could observe a moderate delay before stabilization of basal blood glucose levels, reflecting slightly lower and delayed levels of circulating human c-peptide in these cohorts (Figures 7C 0 and 7D 0 ).
After murine b cell ablation, basal blood glucose concentration was initially between 105 and 125 mg/dL but by 1-2 weeks stabilized lower at 70 to 90 mg/dL ( Figure 7D ). These concentrations are in the range of the reported human set point of 70-120 mg/dL. Resetting of basal blood glucose concentration also occurred in animals implanted with LHiPECs to some extent, but due to the delay in maturation it was less robust on average ( Figure 7D 0 ). Removal of the implants rendered animals strongly hyperglycemic (500-600 mg/dL glucose) ( Figures 7D and 7D  0 ). These data support several conclusions. First, graft-derived endocrine cells are capable of maintaining glucose homeostasis in the absence of mouse pancreatic b cells ( Figure S6 ). Second, rising serum levels of graft-derived insulin as observed over time resulted in a gradual decrease of blood glucose concentrations. Finally, prevention of hyperglycemia in SCID/Bg mice whose endogenous b cells had been destroyed required human graft-derived glucose-stimulated serum levels of human c-peptide of 500 pM (2.3 ng/mL) or more.
DISCUSSION
In this study, we examined the potential of hiPSCs to differentiate into pancreatic progenitors using a four-stage protocol originally developed for hESCs in a scalable process.
Our results show that we could reproducibly and efficiently differentiate hiPSCs into PECs applying both a small-and a large-scale protocol. PECs were qualified by negative expression of CHGA and high levels of expression of PDX1 and NKX6-1 as well as FOXA2. The differentiation efficiency was in a range similar to that previously observed by others for hiPSCs (Nostro et al., 2015) . However, accurate comparison is difficult as there is no consensus on the methods used to quantify the percentage of PECs. Although we did observe a small proportion of mostly polyhormonal endocrine cells as well as cells expressing off-target markers such as intestinal (CDX2) and liver (AFP) markers, we speculate that the glucose-responsive cells arise from pancreatic endoderm-defined cells. This is based on prior work performed on hESC-derived PECs showing that insulin-producing cells generated in vivo derive from sorted PECs, whereas the polyhormonal cells give rise to mainly glucagon cells (Kelly et al., 2011) . Also, others have shown that differentiated populations containing higher proportions of pancreatic progenitor cells expressing PDX1 and NKX6-1 differentiate toward b-like cells either in vivo or in vitro (Kirk et al., 2014; Pagliuca et al., 2014; Rezania et al., 2014; Russ et al., 2015) . Using more recently published protocols with the large-scale three-dimensional system described here, it is likely that the four-stage differentiation protocol could be further optimized to increase the percentage of PECs and decrease the percentage of polyhormonal endocrine cells. This study represents a valid proof of concept that hiPSCderived pancreatic endoderm can be generated in largescale production.
The capacity of hiPSC-derived PECs to survive and mature within planar macroencapsulation devices in vivo was evaluated. Explants of hiPSC-derived b cells in the context of other islet cells generated in vivo secrete human insulin and c-peptide in response to glucose. Furthermore, glucose triggered calcium signaling in the b cells matured in vivo, consistent with normal metabolism-secretion coupling in these cells. Importantly, following more than 12 weeks of implantation, the hiPSC-derived PECs were able to prevent hyperglycemia in 70%-80% of animals after ablation of mouse b cells using STZ. The minimal requirement for STZ-driven hyperglycemia protection in mice was around 500 pM release of human c-peptide, which corresponds to reported maximal concentrations of murine c-peptide secreted after glucose injection. However, the range of glucose-stimulated c-peptide levels measured in insulin-free diabetic patients with functional islet grafts averaged 3-4.5 ng/mL (1,000-1,500 pM) (Hering et al., 2005) , comparable to the 1,456 ± 300 pM levels detected after STZ ablation. The rescue of the STZ-driven hyperglycemia was as efficient as observed after transplantation of hESC-derived PECs or with approximately 2,000 adult human islets (Gaber et al., 2004; Kroon et al., 2008) . In vivo-matured hiPSC-derived PECs tightly controlled glycemia below the levels observed before the STZ ablation, reaching an average of 80 mg/dL for a period of up to 70 days following the STZ treatment. Relative to plasma glucose levels in humans, which are 70-120 mg/dL, the calibrated levels ranged from normoglycemic to slightly hypoglycemic. Hypoglycemia (with respect to normal mouse basal levels) is generally observed in mice and rats upon engraftment of human fetal or adult b cells (Castaing et al., 2001; Tuch et al., 1991) , as well as hESCderived b cells (Kroon et al., 2008) . In this study we decided to assess the maturation of hiPSC-derived b cells under normoglycemic conditions, which do not reflect the clinical conditions of treatment of T1D. However, normoglycemia in mice is perceived as a mild hyperglycemic environment for human PECs with regard to human physiology.
Glucose-stimulated human c-peptide levels were detected in serum around 8 weeks post-implantation for the HiPECs and after 12 weeks for the LHiPECs. In general, large-scale production tended to influence the maturation efficiency of the pancreatic endoderm compared with the small-scale production, an effect that did not appear to be attributable to cryopreservation of PECs (data not shown). The reduction of growth factor concentrations used during the large-scale production to reduce costs may explain the reduced efficiency, although this change did not have an impact on the percentage of PECs obtained at the differentiation endpoint. Notably, some mice implanted with the LHiPECs demonstrated c-peptide kinetics comparable to those of mice implanted with HiPECs, although the proportion of those animals was smaller in the large-scale cohorts. The reason for this difference is unclear; it could be due to variability observed with in vivo experiments or perhaps more variable levels of engraftment with largescale pancreatic endoderm implants. Compared with available data from hESC-derived PEC implantations, or from fetal and adult islet transplantation, the maturation of the hiPSC-derived PECs also seems to be delayed. Interestingly, Robert et al. have shown that the immature features of the hESC-derived b cells in vivo improved over time to reach a functionally mature b cell mass after 1 year of engraftment (Robert et al., 2018) . Time could also possibly improve maturation of hiPSC-derived b cells, but this hypothesis will need to be tested. The delay could also be explained by the macroencapsulation of the cells (Motte et al., 2014) . Indeed, subcutaneous macroencapsulation imposes on the cells a slight delay before full vascularization takes place. We observed that the first blood vessels were established only 10 to 15 days following the implantation. Usually, preferred implantation sites for islets and related cells are the kidney capsule and the epididymal fat pad, which represent highly vascularized sites. As previously reported for hESC-derived b-like cells (Matveyenko et al., 2010) , macroencapsulated HiPECs implanted in nude rats showed only poor c-peptide secretion in 10% of the animals after 20 weeks post-implantation and only if the device was permeabilized, which suggests that vascularization efficiency is even more delayed in nude rats compared with SCID/Bg mice and prevents maturation of the pancreatic progenitors (data not shown). However, this is in contrast with results obtained from Bruin et al., where maturation of insulin-secreting cells from hESCs was accelerated after implantation under the kidney capsule of nude rats (Bruin et al., 2015) . Indeed, a macroencapsulation approach can trigger a foreign body response to the implant, with recruitment of foreign body giant cells that can affect oxygenation of the device and the implanted cells (Franz et al., 2011) . Altogether, these results suggest that tightly controlling vascularization and tissue reaction in macroencapsulated implants is critical for ensuring proper survival and maturation of the cells. Microencapsulation of pancreatic endoderm-derived b-like cells has also been investigated as an alternative requiring accelerated vascularization of the more mature cells (Vegas et al., 2016) . However, an important consideration for this approach is maintaining the integrity of the implanted pancreatic aggregates and avoiding the disruption of the maturing cellular architecture, issues that are often associated with microencapsulation of cells for transplantation.
Recently, considerable progress has been made with the optimization of in vitro strategies to differentiate hESCs into mature insulin-secreting b cells (Pagliuca et al., 2014; Rezania et al., 2014; Russ et al., 2015) . However, these hESC-derived insulin-secreting b cells still have some limitations. For instance, their glucose responsiveness as assessed in vitro remains relatively poor compared with primary human islets. Moreover, gene expression profiling showed that the signature of the newly generated b cells still shared features reminiscent of fetal b cells (Pagliuca et al., 2014; Rezania et al., 2014) . Indeed, such cells either partially rescued hyperglycemia induced by STZ in vivo or rescued hyperglycemia to a similar extent and over the same time frame as PECs, suggesting that their differentiation into fully mature and functional b cells was not complete . It still remains to be proven if the glucose-responsive b cells in these 12 week grafts derived from the originally implanted insulin cells or the contaminating pancreatic endoderm. Moreover, the efficiency of differentiation remains very low compared with levels obtained for the PECs. All these data suggest that we still need to understand the mechanisms driving the functional maturation of b cells to transfer such knowledge in a dish.
In conclusion, these results show that hiPSC-derived endocrine cells generated after implantation of pancreatic progenitors produced in vitro using a scalable process are functionally similar to hESC-derived islets as well as human islets in vivo, supporting evidence that hiPSCs may serve as a renewable source of islets for diabetes cell-replacement therapies.
EXPERIMENTAL PROCEDURES
Cell Culture and Differentiation hiPSCs, provided by Fujifilm Cellular Dynamics (Madison, WI, USA), were maintained on mouse embryonic fibroblast feeder layers (Millipore, PMEF-N). Cell culture was performed in humidified incubators at 37 C and 8% CO 2 . Small-and large-scale expansion and differentiation were carried out under three-dimensional conditions using an optimized version of the four-stage protocol for which details are explained in the Supplemental Experimental Procedures.
Cryopreservation and Banking of HiPECs
LHiPECs (day 12) were resuspended in cryopreservation medium (90% KOSR/10% DMSO/25 mM HEPES), cryopreserved using a controlled-rate freezer (Planer plc Kryo 560-16) using a specific program (Supplemental Experimental Procedures) and banked in liquid nitrogen.
Encapsulation and Implantation
Cell aggregate slurry was transferred in S4 culture medium and loaded into a flat sheet encapsulation device based on a polymeric frame technology as described previously (Supplemental Experimental Procedures) (Lathuiliere et al., 2014) . Encapsulation devices were implanted dorsolaterally in male SCID/Beige mice (Charles River) 6-13 weeks of age. All animal experiments were carried out in accordance with the Swiss regulation on animal experimentation and the European Council directive (86/609/EEC) for the care and use of laboratory animals (EXPANIM-SCAV protocol approval VD2569).
STZ Treatment of Mice
At 20-25 weeks post-implantation, mice received 70 mg STZ per kilogram body weight (Sigma, S0130), through intraperitoneal injection for 5 consecutive days for a total dose of 350 mg/kg. When implanted animals reached blood glucose levels higher than 300 mg/dL for at least 7 consecutive days, the animals were euthanized.
Ex Vivo Histological Analysis
Encapsulation devices were retrieved and fixed in 4% paraformaldehyde for 4-7 days, dehydrated, and processed for paraffin embedding. Samples were sliced on a microtome at a thickness of 5 mm and stained with H&E. Insulin staining was revealed by immunohistochemistry using human insulin antibody (Dako, A0564) and images were acquired with a bright-field microscope (Leica) with a 103 objective (Supplemental Information).
Human Islets Preparation
Human islets from non-diabetic deceased donors were purchased from tebu-bio, providing donor consent forms for medical research. Islets were cultured at 37 C in a humidified atmosphere (5% CO 2 ). Details on culture medium are provided in Supplemental Experimental Procedures. Human islets were sampled after a maximum 4 days in culture for RNA analyses. All human islet procedures were approved by Comission cantonal d'étique de la recherche sur l'être humain (306/14).
Gene Expression Analyses
Total RNA from aggregates, human islets, or explanted tissue was isolated, quantified, and qualified using specific commercial kits (detailed information in Supplemental Experimental Procedures). Gene expression analysis was performed using the NanoString nCounter gene expression assay with100 ng RNA per reaction and the Combo_6980 code set according to the manufacturer's instructions (NanoString). Detailed information on code set and analysis of the data are provided in Supplemental Experimental Procedures. The average and standard deviations of the fully normalized counts were calculated for two biological replicates.
Immunofluorescence and High Content Image Analyses
D12 aggregates or explants were cryopreserved and embedded in 7.5% gelatin (details provided in Supplemental Experimental Procedures). The whole explant/aggregates were sectioned at À28 C in 4 mm thick sections using a microtome, and for each staining, tissue was analyzed every 40 mm. Immunofluorescence was performed using standard methods detailed in Supplemental Experimental Procedures. Details of primary and secondary antibodies are listed in Table S2 . Images were acquired with an Axio Imager M2 Zeiss microscope. For high content image analyses and quantifications, whole slide images were acquired using an Olympus Slide Scanner (VS120-SL) with a 103 objective, which is suitable for quantification. Quantification was done using MetaXpress. Details of quantifications are provided as Supplemental Experimental Procedures.
Flow Cytometry Analyses
Single-cell suspensions of D12 HiPECs were obtained by dissociating cells with Accumax (Innovative Cell Technologies, AM105) at 37 C for 15 min. Live/dead staining (Thermo Fisher L34963) was performed for 20 min at room temperature. For intracellular antibody staining, cells were fixed using Fix/Perm buffer (Bioscience, 00-5523-00) for 30 min at room temperature and then washed with Perm buffer. Cells were re-suspended in 100 mL Perm/Wash buffer and then incubated overnight at 4 C with 50 mL primary antibodies mix. Details of antibodies are listed in Table S3 . Dead cells were excluded during flow cytometry analysis and gating was determined using isotype antibodies. Flow cytometry data were acquired on a Becton Dickinson FACS FORTESSA and analyzed using De Novo FCS express software.
Glucose-Stimulated C-Peptide Secretion Assay and Intraperitoneal Glucose Tolerance Assays
Following overnight fasting, animals received an intraperitoneal injection of a 30% glucose (dextrose) solution dosed at 3.0 g/kg body weight. Blood samples were collected before and following the glucose injection at 15, 30, and 60-120 min. To evaluate the c-peptide release ex vivo, the explants were retrieved from the devices. Human c-peptide concentration in sera or supernatant samples was determined using the Ultrasensitive Human c-peptide ELISA as described by the manufacturer (Mercodia, 10-1141-01). Blood glucose levels were measured with glucometer strips and the glucometer Accu-Chek (Aviva).
Calcium Signaling Analyses
Explants were partially digested with Accumax at 37 C and plated on 35 mm diameter glass-bottom dishes (MatTek, P35G-1.5-20-C) coated with 804G matrix (Langhofer et al., 1993) contributed to the study design and to the manuscript. M.R-C.K. designed the study, analyzed data, and wrote the manuscript. M.R-C.K. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
